Nazir Khan v. Iftikhar Khan — Federal Circuit Appeal Dismissed in 57 Days
Nazir Khan brought an infringement appeal against Iftikhar Khan at the Court of Appeals for the Federal Circuit over US8747344B2, a patent covering a hybrid arteriovenous shunt. The Federal Circuit dismissed the appeal, ordering each party to bear its own costs, closing the matter in under two months.
Federal Circuit dismisses AV shunt infringement appeal without merits ruling
Nazir Khan filed an infringement appeal on 22 January 2026 at the Court of Appeals for the Federal Circuit, naming Iftikhar Khan as defendant. The single patent at issue is US8747344B2 (application no. US13/645862), which covers a hybrid arteriovenous shunt — a vascular access device used to create a connection between an artery and a vein, typically in dialysis patients. The case was assigned to the Federal Circuit and designated as an infringement action.
The recorded Basis of Termination is 'Appeal Dismissed.' The court's order states: the appeal is dismissed and each party shall bear its own costs. No merits determination regarding infringement or validity of US8747344B2 was reached at this appellate stage. The specific procedural grounds for the dismissal are not disclosed in the available record.
The case closed on 20 March 2026, just 57 days after filing — an unusually short lifespan for a Federal Circuit appeal, which suggests the dismissal was procedural in nature rather than the product of extended substantive briefing. What drove the dismissal, and whether the underlying infringement dispute remains live in any forum, is not disclosed in the available record.
See Complete Case & Patent Analysis →Filing to Appeal Dismissed in 57 days
Days from filing to dismissal — notably swift resolution at appellate level
US8747344B2 — hybrid arteriovenous shunt for vascular access
Any company developing, manufacturing, or commercialising hybrid arteriovenous shunt devices or adjacent vascular access technologies should treat US8747344B2 as an active risk factor. This Federal Circuit appeal produced no merits ruling, meaning the patent has not been declared invalid or non-infringed by any court in this proceeding. Medical device R&D teams working on dialysis access, AV fistula systems, or hybrid graft-fistula constructs are the primary audience for an FTO review of this patent.
Official order — verbatim text
The Federal Circuit's order dismisses the appeal and directs each party to bear its own costs. The order does not address the merits of the infringement claims under US8747344B2, meaning no appellate determination on validity or infringement was reached. The equal costs direction is consistent with a procedural termination rather than a substantive ruling favouring either party.
Appeal dismissed: what the Federal Circuit's order means for both parties
Procedural dismissal — no merits adjudication
A dismissal at the appellate level means the Federal Circuit did not reach the substance of the infringement claims. The court's order terminates the appeal without affirming, reversing, or vacating any lower decision on US8747344B2. The specific procedural grounds — whether jurisdictional, for failure to prosecute, or another basis — are not disclosed in the available record.
No merits rulingNazir Khan's appeal ends without a finding on infringement
As appellant, Nazir Khan obtained no merits determination from the Federal Circuit on the infringement claims tied to US8747344B2. The dismissal means any relief sought on appeal was not granted at this stage. Whether avenues to re-assert the patent in another forum remain open is not determinable from the available record.
No appellate relief obtainedIftikhar Khan avoids a Federal Circuit merits ruling
The dismissal means no appellate finding of infringement was entered against Iftikhar Khan. However, because the dismissal is procedural rather than a ruling on the merits, it does not constitute a definitive determination that US8747344B2 was not infringed. Each party bears its own costs, meaning no cost liability was imposed on the respondent.
No merits finding against defendantUS8747344B2 validity and enforceability remain unaddressed
Because the Federal Circuit did not rule on the merits, the validity and enforceability of US8747344B2 covering the hybrid arteriovenous shunt technology are unresolved by this proceeding. Competitors and licensees in the vascular access device sector should note that the patent's legal status was not adjudicated here. Monitoring further proceedings around this patent is advisable.
Patent status unresolvedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Nazir Khan | Individual | /Search in Eureka ↗ |
| Defendant | Iftikhar Khan | Individual | /Search in Eureka ↗ |
| Plaintiff counsel | Nazir Khan | Attorney | Counsel for Nazir KhanSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
R&D signals in the hybrid arteriovenous shunt patent space
Forward-looking patent intelligence around hybrid AV shunt technology, vascular access device innovation, and the IP positions of the parties in this Federal Circuit appeal.
Nazir Khan's patent activity in vascular access technology
US8747344B2 (app. US13/645862) is the asserted patent in this appeal. Mapping Nazir Khan's broader filing activity — including any continuations, divisionals, or related applications — can reveal the depth of IP coverage being built around hybrid arteriovenous shunt designs and inform competitive risk assessments for medical device developers.
Plaintiff patent portfolioFiling trends in hybrid AV shunt and vascular access device patents
Hybrid arteriovenous shunts sit at the convergence of dialysis access, interventional nephrology, and minimally invasive vascular surgery. Tracking patent filing trends in this domain can surface which organisations are actively innovating, whether claim scope is broadening or narrowing, and where white space exists for next-generation access device designs.
AV shunt filing trendsIftikhar Khan's patent posture in vascular access innovation
Understanding whether Iftikhar Khan holds independent IP in the arteriovenous shunt or related vascular access space can clarify the competitive dynamic underlying this dispute. A respondent with their own patent portfolio may signal a cross-licensing context or a technology rivalry worth monitoring for future filings or disputes.
Respondent patent activityAdjacent innovation opportunities near hybrid AV shunt technology
The hybrid arteriovenous shunt concept bridges synthetic graft and native fistula approaches. Adjacent white space may exist in biocompatible coating innovations, flow-regulation mechanisms, implantable sensor integration, or minimally invasive deployment systems — areas where patent density around US8747344B2's claim scope may be lower and novel IP positions more achievable.
Vascular access white spaceSimilar Federal Circuit patent appeals in vascular access and medical devices
Explore comparable infringement appeals dismissed at the Federal Circuit involving medical device patents in the vascular access and dialysis access technology space.
What this case signals for the vascular access device IP landscape
A procedural Federal Circuit dismissal leaves the hybrid AV shunt patent's enforceability open — a signal worth tracking for the vascular access sector.
Procedural dismissals leave patent enforceability unresolved
US8747344B2 was never adjudicated on the merits at this appellate stage. Companies operating in the hybrid arteriovenous shunt space cannot rely on this dismissal as a clearance event. An independent freedom-to-operate analysis against US8747344B2 remains the appropriate risk-management step.
57-day lifespan suggests early procedural termination
Appeals resolved at the Federal Circuit in under two months typically indicate a procedural rather than substantive disposition — such as a jurisdictional defect or failure to meet filing requirements. This pattern suggests the underlying dispute may not have been fully exhausted, and further proceedings in another forum cannot be ruled out from the available record.
Khan v Iftikhar — key questions answered
The Court of Appeals for the Federal Circuit dismissed the appeal in Case No. 26-1364. The court's order states: the appeal is dismissed and each party shall bear its own costs. No merits ruling on the infringement claims under US8747344B2 was issued. The case closed on 20 March 2026, 57 days after filing.
The patent at issue is US8747344B2 (application no. US13/645862), covering a hybrid arteriovenous shunt — a vascular access device that creates a connection between an artery and a vein, used in contexts such as haemodialysis. The case was brought as an infringement action before the Federal Circuit.
No. The dismissal was recorded as 'Appeal Dismissed' without a merits ruling. The Federal Circuit did not adjudicate the validity or infringement of US8747344B2 in this proceeding. The patent's legal status is unresolved by this case, and the dismissal cannot be treated as a clearance event by third parties.
The 57-day lifespan from filing to dismissal is notably short for a Federal Circuit appeal, which typically involves extended briefing schedules. This timeline suggests the dismissal was procedural in nature — potentially jurisdictional or for failure to meet appellate filing requirements. The specific grounds for dismissal are not disclosed in the available record.
The Federal Circuit's order directs each party to bear its own costs. No cost award was made in favour of either Nazir Khan or Iftikhar Khan. This is consistent with a procedural dismissal where no prevailing party on the merits is identified.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.